Hainan Tongyong Kangli Pharmaceutical Co., Ltd.

1. It can obviously inhibit the synthesis of thromboxane A2 (TXA2), counteract the platelet aggregation caused by arachidonic acid (AA), and has a stronger and faster antiplatelet aggregation effect than aspirin (ASP). 2. It can enhance the fibrinolytic activity and promote the dissolution of thrombus. 3. It can reduce the specific viscosity of whole blood and plasma, and accelerate the electrophoresis of red blood cells. 4. It can relax the vascular smooth muscle, dilate the artery, and increase the blood flow of the coronary artery and cerebral artery. 5. It can improve the ability to resist hypoxia. 6. It can strongly scavenge free radicals. 7. It can inhibit the inflammatory exudation of capillaries.

This product is a semi-synthetic aminoglycoside antibiotic with strong antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, indole-negative and -positive Proteus, Klebsiella, Acinetobacter, Citrobacter, and some strains of Serratia and Enterobacter. It also has good antibacterial effects on Mycobacterium tuberculosis, atypical mycobacteria and Staphylococcus aureus (enzyme-producing and non-enzyme-producing strains). Other Gram-positive bacteria (including Streptococcus faecalis), anaerobic bacteria, Rickettsia, fungi and viruses are not sensitive to this product. This product is stable to aminoglycoside acetyltransferase AAC (3), so it can produce this enzyme. Strains resistant to kanamycin, gentamicin, tobramycin and sisomicin are sensitive to this product. This product can often achieve synergistic effects when used in combination with beta-lactams. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. Animal test data indicate that this product has lower ototoxicity than gentamicin and tobramycin, and lower nephrotoxicity than gentamicin.

This product is a component of parenteral nutrition. It can be decomposed into glutamine and alanine in the body, and glutamine can be supplemented through parenteral nutrition infusion. The released amino acids are stored in the corresponding parts of the body as nutrients and metabolized according to the needs of the body. This product can be used for parenteral nutrition support for diseases that may cause glutamine depletion in the body.

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

It has α receptor blocking and vasodilation effects. It can enhance brain cell energy metabolism and increase the utilization of oxygen and glucose. It can promote the conversion of the neurotransmitter dopamine to enhance nerve conduction, strengthen brain protein biosynthesis, and improve brain function. Toxicity tests have failed to show that nicergoline has teratogenic effects.